LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma.

CONCLUSIONS: MYLK-AS1 and E2F7 are closely related to some malignant clinicopathological features and prognosis of HCC, thus the MYLK-AS1/ miR-424-5p/E2F7 signaling pathway might represent a promising treatment strategy to combat HCC. PMID: 33168027 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33168027?dopt=Abstract

Source: Clin Med Res - November 9, 2020 Category: Research Authors: Teng F, Zhang JX, Chang QM, Wu XB, Tang WG, Wang JF, Feng JF, Zhang ZP, Hu ZQ Tags: J Exp Clin Cancer Res Source Type: research